TNG-462 is an orally active, potent and selective inhibitor of methylthioadenosine (MTA)-cooperative PRMT5. It exhibits significant antitumor activity, including durable regressions and complete responses, against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation solid tumors.